Bullish indicating open at $55-$60, IPO prices at $37
HORSHAM, Pa. - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company with $32.67 million in trailing twelve-month revenue and a market capitalization of $10.89 million, has announced the publication of a study that underscores the effectiveness of its Excimer Laser technology. According to InvestingPro analysis, the company maintains a healthy gross margin of 55.47%, despite currently trading near its 52-week low. The peer-reviewed research, conducted by experts from Nippon Medical School and published in the Journal of Nippon Medical School, compares the Excimer Laser with other UVB light sources in treating skin conditions such as vitiligo, psoriasis, alopecia areata, and atopic dermatitis.
The study reveals that the Excimer Laser, due to its high repetition rate and high dose, achieves deeper penetration into hair follicles, targeting melanocyte stem cells crucial for pigmentation. This leads to superior clinical outcomes, including enhanced re-pigmentation and fewer epidermal side effects compared to Excimer Light. Wall Street analysts maintain a positive outlook on STRATA’s technology, with InvestingPro data showing a consensus Buy rating and price targets suggesting significant upside potential.
The Excimer Laser’s precise, monochromatic light allows for targeted treatment, reducing the number of sessions and cumulative doses required. Its high irradiance also shortens exposure time, minimizing skin stress while maximizing treatment efficacy.
Dr. Dolev Rafaeli, President and CEO of STRATA Skin Sciences, highlighted the study’s significance, stating it further validates the company’s advanced technologies. STRATA has seen success with the XTRAC Excimer Laser in Japan, where over 100 devices have been placed since its 2019 launch, contributing to the goal of replacing older VTRAC Excimer Light devices.
The company’s growth in Japan complements its global footprint, with over 1,800 Excimer Laser devices in the United States and more than 1,000 internationally. STRATA Skin Sciences remains committed to delivering innovative treatment solutions globally. InvestingPro analysis indicates the stock is currently undervalued, with a Fair Value assessment suggesting upside potential. Subscribers can access the comprehensive Pro Research Report, which provides detailed analysis of STRATA’s financial health, market position, and growth prospects among 1,400+ top stocks.
This study adds to the body of evidence supporting Excimer Laser technology’s benefits for treating autoimmune dermatological diseases. The findings are based on a press release statement from STRATA Skin Sciences, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.